Heart Surgery vs Stents Show Equal 5-Year Survival in Major Coronary Disease Study
FAME 3 trial finds no difference in death, stroke, or heart attack rates between bypass surgery and stents at 5 years, though stents had more complications.
Summary
The landmark FAME 3 trial followed 1,500 patients with severe three-vessel coronary artery disease for five years, comparing modern stent procedures (PCI) to bypass surgery (CABG). Results showed no significant difference in the combined rate of death, stroke, or heart attack between treatments. However, patients receiving stents experienced higher rates of heart attacks and needed more repeat procedures compared to those who had bypass surgery.
Detailed Summary
This study addresses a critical question for the millions facing severe coronary artery disease: whether modern stent procedures can match the long-term benefits of traditional bypass surgery. The FAME 3 trial represents the most comprehensive comparison to date, using advanced fractional flow reserve (FFR) guidance to optimize stent placement.
Researchers followed 1,500 patients across 48 hospitals worldwide for five years. All participants had three-vessel coronary disease but were otherwise stable candidates for either procedure. Half received FFR-guided stent placement with current-generation drug-eluting stents, while half underwent coronary artery bypass grafting.
The primary finding was reassuring: no significant difference existed in the combined rate of death, stroke, or heart attack at five years (16% for stents vs 14% for surgery). Death rates were virtually identical between groups. However, important differences emerged in secondary outcomes.
Patients who received stents experienced significantly more heart attacks (8% vs 5%) and required repeat procedures twice as often (16% vs 8%). These findings suggest that while both treatments offer similar protection against the most serious outcomes, bypass surgery provides more durable protection against future cardiac events.
These results will inform treatment decisions for patients and doctors worldwide, providing contemporary evidence that both approaches remain viable options for treating severe coronary disease, each with distinct risk-benefit profiles.
Key Findings
- No difference in 5-year death, stroke, or heart attack rates between stents and bypass surgery
- Stent patients had 60% higher heart attack risk compared to bypass surgery patients
- Repeat procedures needed twice as often with stents versus bypass surgery
- Death rates identical between treatments at 7% for both groups at 5 years
Methodology
Multicenter randomized trial of 1,500 patients with three-vessel coronary disease across 48 hospitals. Patients were randomly assigned to FFR-guided PCI with drug-eluting stents versus coronary artery bypass grafting, with 5-year follow-up achieved in 95% of participants.
Study Limitations
Summary based on abstract only as full text was not available. Study was industry-funded by Medtronic and Abbott Vascular. Results may not apply to patients with left main coronary disease or those with recent heart attacks, who were excluded from the trial.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.